ambrisentan (Volibris®)

Reference No. 20

Publication date:

11/06/2009

Appraisal information

ambrisentan (Volibris®) 5 mg film-coated tablet
ambrisentan (Volibris®) 10 mg film-coated tablet

Company:	GlaxoSmithKline
BNF category:	Cardiovascular system
NMG meeting date:	12/11/2008
AWMSG meeting date:	29/04/2009

Submission Type:	Independent Review
Status:	Recommended
Advice No:	2508
Ministerial ratification:	10/06/2009

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ministerial
Ratification

AWMSG advice

Ambrisentan (Volibris®) is recommended for use within NHS Wales for the treatment of patients with pulmonary arterial hypertension (PAH) classified as World Health Organisation (WHO) functional class (FC) II and III, to improve exercise capacity. Ambrisentan (Volibris®) is restricted for use as directed by a physician experienced in the treatment of PAH at one of the National Commissioning Group (NCG) centres across the UK. Ambrisentan (Volibris®) is not considered suitable for shared care within NHS Wales.

Final Appraisal Recommendation (FAR)

Download

ambrisentan (Volibris) 20 FAR